NYSE:PFE News 16 August 2025

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Stock Price & Recent Performance Before the late-September rally, Pfizer’s stock had been trading lethargically. As one analysis notes, PFE closed around $23.60 on Sept. 26, roughly flat for the year and down ~9% since January ts2.tech. Over the prior

19 October 2025

Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

Key Facts – October 18, 2025 Nasdaq Ends Week Higher Amid Roller-Coaster Trading After a roller-coaster week, the Nasdaq Composite Index managed to finish in positive territory, showcasing resilience in the face of multiple risk flare-ups. The index closed Friday

18 October 2025

Financial News · Investing · Market Analysis · NASDAQ:AMD · NASDAQ:AVGO · NASDAQ:KLAC · NASDAQ:NVDA · NASDAQ:WAL · NASDAQ:ZION · NYSE:LLY · NYSE:PFE · Stock Market · Technology

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a

6 October 2025

Business News · Healthcare · Investment Trends · NYSE:LLY · NYSE:NVO · NYSE:PFE · Pharma Industry · Stock Market

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Market commentary and outlook Lara Castleton of Janus Henderson noted that Tuesday’s White House–Pfizer announcement “was the catalyst for healthcare,” freeing up investors to rotate into the beaten-down sector reuters.com. Kyle Rodda at Capital.com observed that the weak ADP report

2 October 2025

Economic News · Finance · Market Trends · NASDAQ:MU · NASDAQ:STX · NASDAQ:WDC · NYSE:AES · NYSE:LLY · NYSE:PFE · Stock Market · U.S. Economy

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Share Price & Recent Performance In early September 2025, Pfizer (NYSE:PFE) was trading in the mid–$20 range. After a relatively quiet first weeks of the month, the stock exploded higher at month-end. On Sept. 30, PFE closed at $25.48 after soaring

2 October 2025

Business Trends · Healthcare News · Investing · NYSE:PFE · Pharmaceutical Industry · Stock Market

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Overview Index Performance The 1 October 2025 session began under a cloud as the federal government shut down due to a budget impasse. Stock futures opened lower amid fears that key economic reports might be delayed investopedia.com. By the closing bell,

1 October 2025

Economic News · Financial Trends · Investment Insights · Market Analysis · NASDAQ:AZN · NASDAQ:BIIB · NYSE:LLY · NYSE:PFE · NYSE:TMO · Stock Market

Stocks Rally to Record Highs as Shutdown Looms – Dow and S&P Post Best September in 15 Years

Market Performance (Sept. 30 & Oct. 1) U.S. stock markets closed Sept. 30 higher, ending the month on a positive note. The S&P 500 closed at 6,688.46 (+0.41%), the Dow at 46,397.89 (+0.18%), and the Nasdaq at 22,660.01 (+0.31%) reuters.com.

1 October 2025

Dow Jones · Economic News · Market Records · NYSE:PFE · S&P 500 · Stock Market

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

What Is “TrumpRx”? A Direct-to-Consumer Drug Website “TrumpRx” is a planned federal website that will let Americans buy prescription medicines directly from the government at cash prices. According to administration officials, TrumpRx will negotiate discounted rates with drugmakers and allow

30 September 2025

Healthcare · NYSE:PFE · Pharmaceuticals · Policy · Politics · US News

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

Stock Performance (Sep 2025) On Sept 30, 2025 Pfizer closed around $24.40 reuters.com. Over the past year PFE underperformed the pharma sector (latest 52-week range ~$20.91–30.43 reuters.com). Its trailing P/E is 12.64× reuters.com (ex. special items) and forward P/E ~7.7×

30 September 2025

Business News · NYSE:PFE · Pharmaceuticals · Stock Market · Stocks · Trump Administration · Weight Loss

Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Industry & Corporate Developments Mergers, Acquisitions & Partnerships Regulatory & Drug Approval Updates Public Health & Policy Research & Clinical Breakthroughs Sources: Reuters, Politico, HealthLeaders, BioPharma Dive, FierceBiotech, Pharmaceutical Executive, Technology Networks, McGill University reuters.com reuters.com healthleadersmedia.com reuters.com fiercebiotech.com reuters.com

21 August 2025

Biotech · Healthcare · Industry News · Medical Innovations · NASDAQ:CRL · NYSE:LLY · NYSE:MDT · NYSE:NVO · NYSE:PFE · NYSE:TAK · Pharmaceuticals

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

New Drug Approvals & Clinical Trial Results Mergers, Acquisitions & Partnerships (No other major M&A deals were announced during Aug 17–18, but this Lilly-Superluminal alliance highlights the continued investment in AI-driven R&D.) Regulatory & Policy Updates Public Health & Epidemiology

18 August 2025

Biotech · Health · Medical News · NASDAQ:GBT · NASDAQ:MDGL · NASDAQ:TNXP · NYSE:NVO · NYSE:PFE · Pharma · Research

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy (semaglutide) received FDA accelerated approval to treat metabolic dysfunction-associated steatohepatitis (MASH), becoming the first GLP-1 therapy cleared for MASH in a patient population estimated at about 5% of U.S. adults, based on part 1 of an ongoing trial showing

16 August 2025

Biotechnology · Health News · Medical Innovations · Mergers & Acquisitions · NASDAQ:BNTX · NASDAQ:CVAC · NASDAQ:TNXP · NYSE:LLY · NYSE:NVO · NYSE:PFE · Pharmaceuticals

NYSE:PFE News 16 August 2025 - 19 October 2025